Preferred Label : KRAS G12C Inhibitor LY3499446;
NCIt related terms : LY-3499446;
NCIt definition : An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with
potential antineoplastic activity. Upon oral administration, LY3499446 targets and
covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C,
thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family
of oncogenes, serves an important role in cell signaling, division and differentiation.
Mutations of KRAS may induce constitutive signal transduction leading to tumor cell
growth, proliferation, invasion, and metastasis.;
UNII : QZJ1I2EN1V;
CAS number : 2409131-50-4; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2409131-50-4
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : LY 3499446; LY-3499446;
NCI Metathesaurus CUI : CL971660;
Origin ID : C166410;
UMLS CUI : C5237964;
Semantic type(s)
- concept_is_in_subset
- has_target
